Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Launches First Overseas Office in Beijing

This article was originally published in PharmAsia News

Executive Summary

U.S. HHS Secretary Michael Leavitt and U.S. FDA Commissioner Andrew von Eschenbach officially opened the first overseas FDA office Nov. 19 in Beijing in a continuing effort to improve foreign product safety, while the agency faces criticism from the U.S. Congress

You may also be interested in...



Biden’s Visit Highlights China-U.S. Cooperation On API Oversight And Patent Protection

Last week, U.S. Vice President Joe Biden visited China, Japan, and South Korean during a six-day Asia trip. One of Biden’s goals in China was to strengthen collaboration between the two countries on food and drug safety as well as patent protection.

China 2014 Regulatory Outlook: Expect Greater Enforcement As CFDA Rolls Out New Regs

The year 2014 could see China FDA implement a series of rules, including revisions to the Drug Registration Regulation and the Medical Device Administration Regulation, which could significantly impact the pharmaceutical and medical device industries.

China 2014 Regulatory Outlook: Expect Greater Enforcement As CFDA Rolls Out New Regs

The year 2014 could see China FDA implement a series of rules, including revisions to the Drug Registration Regulation and the Medical Device Administration Regulation, which could significantly impact the pharmaceutical and medical device industries.

Related Content

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel